The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hi all, I'm tempted to buy into RIO after reading about their tasty dividends on Motley Fool. But a bit put off by the RNS on 6th March about the ongoing SEC proceedings. Can someone shed some more light on what this was all about and what the potential damage to RIO might be?
The RNS also says RIO have settled with the ASIC for AUD$750k, and cases against Albanese and Elliott dismissed. There were also issues with the FCA (settled) and they did have a class action is a US court. That is a lot of legal and regulatory issues, and makes me nervous - what other dodgy dealings are going on that will one day be exposed?
Keen to hear what other people make of this
Since omicron has become dominant, and with the news focus being taken up by the Russia-Ukraine war, I assume that the COVID bubble has well and truly burst? Can we expect that over the next six months most COVID stocks will continue down to their pre-pandemic share prices?
Very good final results.
- most indicators up about 10%
- after-tax profit and earnings per share almost doubled
- dividend up about 7%
- £46m share buy-back (about 3% of market cap)
Back in Dec 2020 several dirctors sold off large amounts of stock. At the time I beleived that signalled their lack of confidence in the company and share price. I posted about it in the thread "RNS - yet more directors sell out" (about here https://www.lse.co.uk/ShareChat.asp?ShareTicker=PUR&share=Pure-Gold-Min&page=63)
Since Dec 2020 PURs share price steadily dropped about 70% from 150 to around 45 today. I feel my prediction was vindicated.
I note the recent RNSs showing directors now buying significant amount of shares. Based on this, I predict that it is reasonable to expect the share price to rise, or at least that the company is in a better position now than in Dec 2020.
The RNS claims the test is perfectly accurate at detecting COVID when it's there and also perfectly accurate at not detecting COVID when it's not there. Does anyone know how that actually evaluate the PCR tests? What do they compare the PCR test result against?
I really don't understand why there is such panic in the media about COVID in India. Everyone seems to forget that India has a population of 1.4 *billion* so of course the absolute numbers look high. But COVID cases and deaths as a proportion of population is still way below the US or the UK.
https://www.worldometers.info/coronavirus/
In my 10 minutes of googling, I think this bought deal is good news for investors. The SP is currently 85p, but the Underwriters have paid 88p ($1.52 CAD = 88p GBP). It also means the Underwriters are reasonably confident the SP will rise in the future. In addition, I believe the flow-through shares allows PUR to write off a significant amount of tax, which should help the bottom line.
I don't understand what the "bought deal" is nor what it means for the share price. Can anyone explain it?
The RNS clearly states "For clarity, the gross origination also includes commercial opportunities postponed or lost/ not eligible."
The £2.4bn figure on its own is useless as a guide for any future sales. We need that £2.4bn broken down into those categories (lost, not eligible, postponed, in progress, etc.)
I'm also curious why in all the EU, there is only Italian companies...
@WolfofWarks Yes, I think you're right. The RNS says this:
"Gross origination" includes all client companies that have signed an NDA, a term sheet, or are in, or have completed, the onboarding process. For clarity, the gross origination also includes commercial opportunities postponed or lost/ not eligible.
So part of the £2.4bn gross originations figure includes lost opportunities. So if a client company was interested, began the process and was prepared to put up £2bn, then pulled out, then that £2bn is INCLUDED in this gross originations figure.
The figure cannot be used as a measure to gauge any future revenue - it is meaningless.
It is already known that the biggest predictors of COVID severity/death is age and certain other pre-existing medical conditions (heart disease, respiratory problems, dementia, etc.) How well does EpiSwitch perform compared to these existing predictors (which do not require a blood test to discover)?
I believe the reason bitcoin is falling is the perceived increased stability surounding the Trump/Biden transfer. There is still an underlying background of perceived uncertainty and instability regarding the pandemic, and this has seen bitcoin increase over the last year.
My random prediction: it will open on 167, 4% up on yesterday's close, and close today 6% up overall at around 170. This is based on the impending move from AIM to the main market.